Prognostic importance of metabolic tumor volume, total lesion glycolysis and maximum standardized uptake value in metastatic non‑small cell lung cancer treated with nivolumab

Immune checkpoint inhibitors have transformed the management of advanced non‑small cell lung cancer (NSCLC), but reliable prognostic biomarkers remain limited. The present retrospective, single‑center study evaluated clinical variables and baseline 18F‑fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters in 95 patients with metastatic NSCLC treated with second‑line nivolumab after progression on platinum‑based chemotherapy between January 2021 and August 2025. Whole‑body metabolic tumor volume (MTV), total lesion glycolysis (TLG) and site‑specific maximum standardized uptake value (SUVmax) were derived from pretreatment PET/CT. Progression‑free survival (PFS) and overall survival (OS) were analyzed using Kaplan‑Meier and Cox regression methods. Median PFS and OS were 8.2 and 16.8 months, respectively. High MTV and high TLG, defined using exploratory cohort‑specific median cutoffs, were associated with shorter PFS (P=0.045 and P=0.012, respectively) and shorter OS (MTV, P=0.015; TLG, P=0.002). Higher bone‑metastasis SUVmax was associated with shorter PFS (P=0.020). In exploratory multivariable models, Eastern Cooperative Oncology Group performance status 2‑3 and the presence of brain or adrenal metastases remained associated with shorter PFS and OS, whereas MTV and TLG were not retained. Therefore, baseline metabolic tumor burden showed prognostic associations in univariable analyses but did not demonstrate independent prognostic value after adjustment for major clinical factors. These findings are hypothesis‑generating and require prospective validation before clinical use.

Authors

Institutions

Publication Details

Journal
Oncology Letters
Published
2026-11-18
DOI
https://doi.org/10.3892/ol.2026.15955
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognostic importance of metabolic tumor volume, total lesion glycolysis and maximum standardized uptake value in metastatic non‑small cell lung cancer treated with nivolumab

Seray Saray, Hasan Bozkurt
1 links
Oncology Letters
Lung Cancer Diagnosis and Treatment
article

Prognostic importance of metabolic tumor volume, total lesion glycolysis and maximum standardized uptake value in metastatic non‑small cell lung cancer treated with nivolumab

Seray Saray, Hasan Bozkurt
article en

Abstract

Immune checkpoint inhibitors have transformed the management of advanced non‑small cell lung cancer (NSCLC), but reliable prognostic biomarkers remain limited. The present retrospective, single‑center study evaluated clinical variables and baseline 18F‑fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters in 95 patients with metastatic NSCLC treated with second‑line nivolumab after progression on platinum‑based chemotherapy between January 2021 and August 2025. Whole‑body metabolic tumor volume (MTV), total lesion glycolysis (TLG) and site‑specific maximum standardized uptake value (SUVmax) were derived from pretreatment PET/CT. Progression‑free survival (PFS) and overall survival (OS) were analyzed using Kaplan‑Meier and Cox regression methods. Median PFS and OS were 8.2 and 16.8 months, respectively. High MTV and high TLG, defined using exploratory cohort‑specific median cutoffs, were associated with shorter PFS (P=0.045 and P=0.012, respectively) and shorter OS (MTV, P=0.015; TLG, P=0.002). Higher bone‑metastasis SUVmax was associated with shorter PFS (P=0.020). In exploratory multivariable models, Eastern Cooperative Oncology Group performance status 2‑3 and the presence of brain or adrenal metastases remained associated with shorter PFS and OS, whereas MTV and TLG were not retained. Therefore, baseline metabolic tumor burden showed prognostic associations in univariable analyses but did not demonstrate independent prognostic value after adjustment for major clinical factors. These findings are hypothesis‑generating and require prospective validation before clinical use.

Oncology LettersVol. 33(1)
Ankara Atatürk Eğitim ve Araştırma Hastanesi (TR), Balıkesir Atatürk City Hospital (TR)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon